AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
Pipeline
Solutions for unmet medical needs
We are advancing a pipeline of allogeneic, off-the-shelf virus-specific T cell (VST) therapies to treat or prevent life-threatening viral diseases with limited to no treatment options in immunocompromised patients.
Posoleucel targets six devastating viral pathogens: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and JC virus (JCV), and has the potential to transform care for transplant recipients.
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
(Phase 1b/2)
Pivotal Trial
(Phase 3)
(Phase 3)
Allo-HCT
Treatment of vHC
Allo-HCT
Treatment of AdV
Allo-HCT
Multi-virus Prevention*
Kidney Transplant
Treatment of BKV
Solid Organ Transplant
Multi-virus Prevention*
*Prevention of adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), JC virus (JCV).
Multi-VSTs targeting human metapneumovirus (hMPV), influenza (Flu), parainfluenza virus (PIV), and respiratory syncytial virus (RSV).
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
(Phase 1b/2)
Pivotal Trial
(Phase 3)
(Phase 3)
Allo-/Auto-HCT
Treatment of hMPV,
Flu, PIV, RSV
Flu, PIV, RSV
High-risk general
population*
population*
Treatment of hMPV,
Flu, PIV, RSV
Flu, PIV, RSV
*High-risk general population: immunocompromised cancer patients, the elderly and very young.
Single-VST targeting hepatitis B (HBV).
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
(Phase 1b/2)
Pivotal Trial
(Phase 3)
(Phase 3)
Chronic HBV
HBV Cure
Definitions
Allo-HCT: allogeneic HCT; Auto-HCT: autologous HCT; POC: Proof-of-concept; High-risk general population: immunocompromised cancer patients, the elderly and very young.
Expanded Access Policy
Enrolling in a clinical trial is the most common way that persons who seek access to an investigational drug may receive that drug, and AlloVir’s clinical studies should be the primary route by which patients receive access to AlloVir’s investigational drug(s).
We treat individuals at high risk
Our allogeneic, off-the-shelf VST candidates benefit patients with T cell deficiencies, including transplant recipients, immunocompromised cancer patients, the elderly and the very young, who are at a higher risk of the devastating consequences of viral diseases.
Life-Threatening Viral Infections
- Adenovirus
- BK Virus
- Cytomegalovirus
- Epstein-Barr Virus
- Human Herpesvirus-6
- JC Virus
- Human Metapneumovirus
- Influenza Virus
- Parainfluenza Virus
- Respiratory Syncytial Virus
- Hepatitis B Virus
organ diseases due to uncontrolled viral diseases
Brain
Kidneys
Malignancy
Liver
Lungs
Small/Large Intestine
Bladder
